Ignite Creation Date:
2024-05-05 @ 12:07 PM
Last Modification Date:
2024-10-26 @ 9:20 AM
Study NCT ID:
NCT00249951
Status:
COMPLETED
Last Update Posted:
2012-07-03
First Post:
2005-11-03
Brief Title:
Alkaline Citrate Treatment to Lower the Risk of Nephrocalcinosis in Preterm Infants
Sponsor:
University of Cologne
Organization:
University of Cologne
Study Overview
Official Title:
None
Status:
COMPLETED
Status Verified Date:
2012-06
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
Preterm infants are at risk to develop nephrocalcinosis Incidence numbers vary according to birth weight and gestation age Very low birth weight infants have the highest risk index with 7-10 of preterm infants developing nephrocalcinosis in the patient population We the researchers at the University of Cologne and others found significantly decreased urinary citrate excretion hypocitraturia to be one of the main risk factors Hence we hypothesized that prophylactic treatment with oral alkaline citrate solution Shols solution would help to 1 increase urinary citrate excretion and 2 help to decrease the incidence of nephrocalcinosis
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None